Crestline Management LP Takes $943,000 Position in BioNTech SE (NASDAQ:BNTX)

Crestline Management LP purchased a new stake in shares of BioNTech SE (NASDAQ:BNTX) during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 8,272 shares of the company’s stock, valued at approximately $943,000.

Several other large investors have also recently bought and sold shares of the business. Braidwell LP boosted its holdings in shares of BioNTech by 25.1% during the fourth quarter. Braidwell LP now owns 309,865 shares of the company’s stock worth $35,309,000 after purchasing an additional 62,115 shares during the period. Bridgefront Capital LLC purchased a new position in shares of BioNTech during the 4th quarter valued at $284,000. Baker BROS. Advisors LP purchased a new position in shares of BioNTech during the 4th quarter valued at $5,131,000. Baird Financial Group Inc. raised its holdings in shares of BioNTech by 14.2% during the fourth quarter. Baird Financial Group Inc. now owns 18,589 shares of the company’s stock worth $2,118,000 after acquiring an additional 2,307 shares in the last quarter. Finally, Bamco Inc. NY boosted its position in BioNTech by 12.7% during the fourth quarter. Bamco Inc. NY now owns 20,936 shares of the company’s stock valued at $2,386,000 after purchasing an additional 2,362 shares during the last quarter. 15.52% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

BNTX has been the subject of a number of recent research reports. Canaccord Genuity Group reaffirmed a “buy” rating and set a $171.44 price target on shares of BioNTech in a research note on Tuesday, March 11th. HC Wainwright decreased their target price on shares of BioNTech from $150.00 to $145.00 and set a “buy” rating for the company in a research report on Tuesday, April 1st. Morgan Stanley cut their price target on shares of BioNTech from $140.00 to $132.00 and set an “overweight” rating on the stock in a report on Tuesday. BMO Capital Markets increased their target price on shares of BioNTech from $130.00 to $143.00 and gave the stock an “outperform” rating in a research report on Tuesday, March 11th. Finally, Citigroup reiterated a “buy” rating and set a $140.00 price target (down previously from $145.00) on shares of BioNTech in a research note on Tuesday. Three research analysts have rated the stock with a hold rating, fourteen have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $142.73.

BioNTech Stock Down 2.1 %

Shares of BNTX opened at $92.77 on Friday. The company has a 50-day simple moving average of $98.79 and a 200-day simple moving average of $109.51. The company has a debt-to-equity ratio of 0.01, a quick ratio of 7.21 and a current ratio of 7.33. BioNTech SE has a 52 week low of $76.53 and a 52 week high of $131.49. The firm has a market capitalization of $22.26 billion, a P/E ratio of -44.18 and a beta of 1.35.

BioNTech (NASDAQ:BNTX) last posted its quarterly earnings results on Monday, March 10th. The company reported $1.08 earnings per share for the quarter, topping analysts’ consensus estimates of $0.38 by $0.70. BioNTech had a negative net margin of 15.16% and a negative return on equity of 2.35%. The firm had revenue of $1.19 billion for the quarter, compared to the consensus estimate of $1.24 billion. During the same quarter in the previous year, the company earned $1.90 earnings per share. The business’s revenue was down 19.5% compared to the same quarter last year. On average, equities research analysts expect that BioNTech SE will post -3.88 earnings per share for the current year.

BioNTech Company Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.